Clinical Trial Update: AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial (AdvanTIG-202) evaluating tislelizumab with or without ociperlimab in previously treated recurrent or metastatic cervical cancer has completed w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Ociperlimab (ociperlimab)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: BeiGene | Conditions: Cervical Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-04-27